Want to see XFOR full AI Analyst Report?
XFOR Stock Chart & Stats
$4.29
-$0.07(-10.26%)
At close: 4:00 PM EST
$4.29
-$0.07(-10.26%)
Day’s Range― - ―
52-Week Range$1.35 - $4.83
Previous CloseN/A
Volume769.31K
Average Volume (3M)849.83K
Market Cap
$373.51M
Enterprise Value$242.34M
Total Cash (Recent Filing)$233.72M
Total Debt (Recent Filing)$77.25M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.54
Shares Outstanding94,319,695
10 Day Avg. Volume1,563,980
30 Day Avg. Volume849,827
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue26.88
Enterprise Value/Gross Profit33.84
Enterprise Value/Ebitda-2.70
Forecast
1Y Price Target
$11.67Price Target Upside171.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.73
Revenue Forecast (FY)$9.50M
Bulls Say, Bears Say
Bulls Say
Improved Leverage And Balance-sheet FlexibilityA dramatic reduction in debt to roughly $0.7M from ~$77–78M materially lowers interest and refinancing risk and increases strategic optionality. With sizable equity (~$168M) and assets (~$270M), the company now has more balance-sheet flexibility to fund trials, commercial rollout or M&A without immediate debt pressure.
High And Durable Gross MarginsSustained gross margins near 76–82% indicate favorable product economics for mavorixafor/XOLREMDI and potential scalability. High margins mean that as revenue scales, incremental sales can contribute meaningfully to covering fixed R&D and SG&A, improving long-term path to operating leverage if commercialization execution holds.
Regulatory/commercial Foothold And Pipeline ProgressApproval for WHIM syndrome establishes a commercial product and regulatory validation, creating a revenue base and commercial infrastructure. Concurrent Phase 3 development for additional neutropenia indications expands the addressable rare-disease market and supports multi-year, durable revenue potential if trials succeed and approvals follow.
Bears Say
Persistent And Large Cash BurnConsistent negative operating cash flow (~-$93M TTM) and negative free cash flow (~-$73M TTM) mean the company consumes capital to fund operations and trials. This structural cash burn requires recurrent external financing or large revenue upside; both raise dilution or execution risk over the medium term.
Highly Volatile And Declining Recent RevenueA roughly 74% TTM revenue decline after a prior ramp signals commercialization or collaboration timing issues and unstable demand. Volatile revenue undermines predictable cash generation and makes it harder to scale commercial operations, hampering durable progress toward self-sustaining profitability.
Deep Operating Losses And Negative ReturnsDespite strong gross margins, operating and net losses remain large versus revenue, producing negative returns on equity and continuous capital consumption. Persistently negative profitability pressures equity holders, increases reliance on dilutive financings and may constrain long-term investment in growth if losses persist.
X4 Pharmaceuticals News
XFOR FAQ
What was X4 Pharmaceuticals’s price range in the past 12 months?
X4 Pharmaceuticals lowest stock price was $1.35 and its highest was $4.83 in the past 12 months.
What is X4 Pharmaceuticals’s market cap?
X4 Pharmaceuticals’s market cap is $373.51M.
When is X4 Pharmaceuticals’s upcoming earnings report date?
X4 Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 110 days.
How were X4 Pharmaceuticals’s earnings last quarter?
X4 Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.04.
Is X4 Pharmaceuticals overvalued?
According to Wall Street analysts X4 Pharmaceuticals’s price is currently Undervalued.
Does X4 Pharmaceuticals pay dividends?
X4 Pharmaceuticals does not currently pay dividends.
What is X4 Pharmaceuticals’s EPS estimate?
X4 Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does X4 Pharmaceuticals have?
X4 Pharmaceuticals has 94,319,695 shares outstanding.
What happened to X4 Pharmaceuticals’s price movement after its last earnings report?
X4 Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went up 4.286%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals?
Currently, no hedge funds are holding shares in XFOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (171.95% Upside)
$11.67 (171.95% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 423.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $109.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.55%
12-Months-Change
Fundamentals
Return on Equity
-94.90%
Trailing 12-Months
Asset Growth
107.89%
Trailing 12-Months
Company Description
X4 Pharmaceuticals
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
XFOR Stock 12 Month Forecast
Average Price Target
$11.67
▲(171.95% Upside)
Technical Analysis
Ownership Overview
0.89% Insiders
16.12% Mutual Funds
0.01% Other Institutional Investors
75.84% Public Companies and
Individual Investors